News

Project—which is expected to double plant’s distribution capacity—will be completed by end of Q3.

Citing FDA’s slow guidance, the American Pharmacists Association is requesting delay in November 2023 DSCSA enforcement.

Complex to develop cGMP-compliant, commercial-scale plasmid DNA.

Companies to release variety of options for this sector.

Platform expected to allow customers to meet various logistics requirements, company says.

Expansion expected to help tackle health issues at a faster rate, company says

Annual report finds continuing impact of COVID-19 on global markets

Transaction expected to close early this year

Reflects company’s identity and pharma supply chain impact

North Carolina facility to manufacture Pfizer’s pipeline products

Cold chain company’s supply chain services experience to help facilitate therapy transport

Nottingham location expected to be fully operational by the end of 2023

Platform is expected to streamline batch turnaround times

Acquisition of Texas facility to add 60,000 square feet of manufacturing space to company’s footprint

Provider will be CDMO’s primary material supplier in the lab, clinical, and production settings

Agreement focused on streamlining and automating manufacturing of cell and gene therapies

Partnership aims to lower prescription drug costs and increase price transparency

Global demand for advanced storage devices likely to fuel growth opportunities

Award given in recognition of CDMO’s commitment to promoting sustainable future

New facility expands presence in APAC region, providing additional availability to clients

Phoenix location will be company’s first to focus on high-density microarrays for diagnostic and life science research

Action enables the company to begin offering its unit-load device for shipments

Statistics show a 13.7% decrease compared to November 2021.

Capacity is below 2021 levels

CDMO will be able to produce rAAV commercial grade product

Provides clientele with an augmented drug development solution

Provider’s regulatory affairs, pharmacovigilance services expected to help increase ABC’s portfolio

Semiannual update includes better revenue forecasting and state reporting